MentionFox
Home › funding signals › Saccade
Accelerator · announced

Saccade (YC F26) — World's earliest test for Alzheimer's biomarkers

Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done. Current treatments, including the FDA-approved drugs released in 2024, don't reverse the disease; they only slow it down.

Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.

Opens in a new tab. No signup.

Saccade

New accelerator entry · 2026-10-06 · the record

Fall 2026
batch
2
people
Early
stage
United States of America
region
Open the record →

What the record says

BatchFall 2026
Announced2026-10-06
StageEarly
StatusActive
Team size2
IndustryHealthcare
Sub-industryHealthcare -> Consumer Health and Wellness
SectorsHard Tech, Hardware, Machine Learning, B2B, Healthcare
RegionsUnited States of America, America / Canada
BasedSan Francisco, CA, USA
HiringNo
Sitehttps://saccade.health
Founded2026
YC group partnerGrey Baker

Pitching, partnering or investing alongside them? See who really runs and owns Saccade.

Watch Saccade

Free to see. No signup.

What do you want to do with Saccade?

Get the full cited report on Saccade

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Saccade: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

In their words

Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done. Current treatments, including the FDA-approved drugs released in 2024, don't reverse the disease; they only slow it down. Earlier detection means earlier intervention. Eye movement changes linked to Alzheimer's surface sooner than any other biomarker, up to 15 years before symptoms appear. We deliver a 15-minute VR assessment delivered to patients in longevity clinics: • Tasks: patients perform visual tasks designed by neurologists to trigger a distinct oculomotor response in people with Alzheimer's or on its path • Hardware: our patent-pending attachment connects to any VR headset on the market and captures these eye movement patterns. • Analysis: the patterns are compared against our ML model to produce a risk analysis. Once classified, patients can access new interventions, such as the FDA-approved drugs. They're also referred to longevity practices, neurology practices or both, depending on their stage of decline. Testing for the earliest biomarkers allows the earliest possible intervention. In some cases, that slows the disease enough that patients outlive the onset of symptoms and never face memory loss in their lifetime.

Want the whole picture on Saccade?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Saccade: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Saccade covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    10 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Saccade: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry, from the company's own site, read directly on 2026-10-06 (saccade.health), and from Hacker News, where 1 thread met the matching rule stated beside the count.

RSS

Tools for this story

Each opens in a new tab, filled in for Saccade. With no account yet, you sign up free and land on the result.

Share this page

Just raised? Share it.

Saccade: Accepted into Y Combinator Fall 2026

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-saccade
Last updated 2026-10-07
Primary record: Y Combinator directory entry
Saccade (YC F26) — World's earliest test for Alzheimer's biomarkers. MentionFox, 2026-10-07. https://mentionfox.com/funding/yc-saccade